eligibility_summary
Eligibility: consent, ≥12, ECOG ≤2, warm/cold/mixed AIHA or Evans, Hb <100, failed/intolerant to ≥3 prior therapies, adequate organ function, contraception/negative pregnancy test. Exclude: lymphoproliferative tumor, platelets <20×10^9/L, severe allergy, recent major neuro events, serious cardiovascular disease, malignancy <5 yrs (except treated in situ), active infection (HBV/HCV/HIV/TB/syphilis), severe mental illness, live vaccine <4 wks, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1, single-arm, dose-escalation/expansion study of ThisCART19A, an allogeneic anti‑CD19 CAR‑T cell therapy (gene‑modified T‑cell biological) for relapsed/refractory autoimmune hemolytic anemia/Evans syndrome after ≥3 prior therapies. Mechanism: donor T cells are engineered with a CD19‑specific chimeric antigen receptor, after infusion they recognize and kill CD19+ B cells/plasmablasts, inducing B‑cell aplasia to suppress pathogenic autoantibody production that drives hemolysis. Targets: CD19-expressing B‑lineage cells (naive/memory B cells, plasmablasts) and the humoral autoimmune pathway (autoantibody-mediated RBC destruction). Monitored for safety/efficacy and PK/PD post-infusion.